A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Trial Profile

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2011

At a glance

  • Drugs Erlotinib; Gemcitabine; Motesanib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 16 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top